Increase in STD Vaccines Signals Trouble for Abstinence Industry

Test ticker

Monika Bauerlein,
CEO

Dear Reader,

The next few months are make-or-break for Mother Jones’ fundraising, and we need more online readers to pitch in than have been of late. In "It's Not a Crisis. This Is the New Normal," we take a level-headed look at the brutal economics of journalism, why investigative reporting like you get from us matters, and why we're optimistic we can grow our base of support in a big way—starting with hitting a huge $300,000 goal in just three weeks. Please learn more and donate if you can right now.

The next few months are make-or-break for Mother Jones’ fundraising. We need to raise $300,000 quickly, and we need more online readers to pitch in than have been. Please learn more in "It's Not a Crisis. This Is the New Normal," where we go into the brutal economics of journalism, and what makes Mother Jones unique and worth supporting if you can right now.

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.

Via Feministing, we learn that there is a new shot to prevent chlamydia in the works. It seems STD prevention in the form of needles is the new black. A few weeks back, Cameron plugged this Prospect piece on the new HPV vaccine. The article discussed that low income girls do not have access to the vaccine, due to lack of funding, but are most at risk. Today, Feministing discusses “the clam” as well as what the proliferation of STD-prevention shots could mean for the abstinence-only education industry. (Mother Jones did a profile on this billion-dollar industry in our November/December 2006 issue.)

“If the scientific community continues to develop STD vaccines, abstinence-only programs are going to have to resort to their far-weaker arguments about the emotional/moral consequences of sex rather than the straight-up medical risks.”